SCHEMBL2362083

SCHEMBL2362083

CNC(=O)c1cc(OC)c(C(C)(C)C)cc1-c1ccc[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 1/20 0.38
CYP3A4 P08684 4/20 0.38
HSD17B10 Q99714 1/20 0.37
IMPDH2 P12268 1/20 0.36
IMPDH1 P20839 1/20 0.36
CYP1A1 P04798 1/20 0.36
CD274 Q9NZQ7 1/20 0.35
EPHX2 P34913 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
ALPL P05186 1/20 0.35
GAA P10253 2/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.34
ERBB2 P04626 1/20 0.34
LMNA P02545 2/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B1 P14061 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350724 0.87 NAPRT (0.43) CYP3A4IMPDH2IMPDH1CYP1A1EPHX2
SCHEMBL2349673 0.86 CYP1A1 (0.37) CYP3A4IMPDH2IMPDH1CYP1A1CD274
SCHEMBL3313129 0.85 CYP3A4 (0.36) CYP3A4IMPDH2IMPDH1CYP1A1CD274
SCHEMBL3316087 0.84 MAP4K1 (0.38) CYP3A4IMPDH2IMPDH1CYP1A1CD274
SCHEMBL2354432 0.82 KDM4E (0.40) CYP3A4GAAL3MBTL1LMNAHPGD
SCHEMBL2364475 0.81 CYP3A4 (0.42) CYP3A4IMPDH2IMPDH1CYP1A1EPHX2
SCHEMBL3310183 0.80 KCNH2 (0.37) CYP3A4HSD17B10CYP1A1CD274HPGD
SCHEMBL13329976 0.79 ADRA2A (0.42) CYP3A4IMPDH2IMPDH1CYP1A1ALPL
SCHEMBL2362966 0.79 HCRTR1 (0.36) CYP3A4CYP1A1GAA
SCHEMBL3309855 0.79 HSP90AA1 (0.40) HPGDKDM4EMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B PLK1 2977/4885CYP3A4 423/4885HSD17B10 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.